Secukinumab is
**Core Concept**
Secukinumab is a human monoclonal antibody that targets interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of various autoimmune diseases, including psoriasis, ankylosing spondylitis, and psoriatic arthritis. It works by inhibiting the IL-17A pathway, thereby reducing inflammation and modulating the immune response.
**Why the Correct Answer is Right**
Secukinumab specifically binds to IL-17A, preventing its interaction with the IL-17 receptor on target cells. This inhibition of IL-17A signaling reduces the production of other pro-inflammatory cytokines, such as IL-6 and TNF-alpha, which are involved in the inflammatory cascade. By targeting IL-17A, secukinumab effectively reduces inflammation and modulates the immune response in affected tissues.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as secukinumab is not a TNF-alpha inhibitor, which is a different class of biologic agents used to treat autoimmune diseases.
**Option B:** This option is incorrect as secukinumab is not a Janus kinase (JAK) inhibitor, which is another class of biologic agents used to treat autoimmune diseases by inhibiting the JAK-STAT pathway.
**Option C:** This option is incorrect as secukinumab is not a calcineurin inhibitor, which is a class of immunosuppressive agents used to prevent organ rejection in transplant patients.
**Clinical Pearl / High-Yield Fact**
Secukinumab is a highly effective treatment option for moderate-to-severe psoriasis, with response rates of up to 80% in clinical trials. It is also approved for the treatment of ankylosing spondylitis and psoriatic arthritis.
**Correct Answer:** D. Secukinumab is a human monoclonal antibody that targets interleukin-17A (IL-17A).